FDA Licenses Diabetes Drug Alogliptin, in 3 FormulationsFDA Licenses Diabetes Drug Alogliptin, in 3 Formulations

The new dipeptidyl peptidase IV inhibitor was approved as monotherapy, and in fixed-dose combinations with metformin and pioglitazone. FDA Approvals
Source: Medscape Today Headlines - Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news